ClinicalTrials.gg
DrugBiological

Tafasitamab clinical trials

Also written MOR00208, XmAb5574, Monjuvi and Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer.

studies test it
41
open now
19
in phase 3
5
first study started
2010

How each study uses tafasitamab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the tafasitamab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
31 Jul 2020 · MONJUVI · BLA 761163 (FDA, Drugs@FDA)
European Union
26 Aug 2021 · Minjuvi · EMEA/H/C/005436 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Tafasitamab
35
Tafasitamab-cxix
7

Brand

Monjuvi
9

Development codes

MOR00208
15
XmAb5574
11
MOR208
11
INCMOR00208
4

Other names

Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer
7

Studies by the year they started

41 studies that test it; most in 2023 (8)

Studies that test tafasitamab, by start year
YearStudies
20101
20132
20141
20162
20191
20202
20216
20225
20238
20245
20254
20264

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
11
Phase 2
32
Phase 3
5

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 15 · Other 26

Incyte Corporation (6) · MorphoSys AG (4) · M.D. Anderson Cancer Center (3) · City of Hope Medical Center (2) · University of Washington (2) · Beijing InnoCare Pharma Tech Co., Ltd. (2) · Memorial Sloan Kettering Cancer Center (2) · Incyte Biosciences Japan GK (1)

Often tested with

Tested in the same studies.

Lenalidomide (17) · Rituximab (9) · Acalabrutinib (5) · Venetoclax (3) · Zanubrutinib (2) · Dexamethasone (2) · Glofitamab (2) · Epcoritamab (2)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Tafasitamab is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 10

Studies that test tafasitamab.

Studies

Open first, then newest update. How each study uses tafasitamab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 41

See all 41 studies that test tafasitamab →

Given beside what is tested · 12 — tafasitamab is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with tafasitamab

Codes

What other systems call tafasitamab · ClinicalTrials.gg INT000583

  • MeSH (NLM) C000613469tafasitamabConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) QQA9MLH692TAFASITAMABConfirmed FDA, NLM, Wikidata
  • RxNorm 2387211One source FDA
  • Wikidata Q98078915tafasitamabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C95768TafasitamabOne source FDA
  • DrugBank DB15044One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.